Skip to content

LABNEST

Active Private limited companyfounded 2022active for 4 yearsSint-Margriete-Houtemlaan 12, 8500 KortrijkKBO/BCE: BE 0788.689.380

Lifetime

4 annual accounts with figures on one time axis
peak of €234,227 in 2025
€234,227▲ 40.7%
peak of €163,428 in 2025
€163,428▲ 43.7%
peak of €297,180 in 2024
€164,428▼ 44.7%
€202,541▼ 10.9%
Board1 name since 2022
1 director
Documentsfilings and deeds
24-08-202624 days late
2025micro format
Gross margin from €166,477 to €234,227Result from €113,709 to €163,428Dividend €296,180Equity from €297,180 to €164,428Cash from €241,667 to €88,981

Key points

from the 2025 annual accounts

Equity

€164,428 ▼ 44.7%
297,1802024+163,428Profit-296,180Dividend164,4282025

LABNEST paid out €296,180 in dividends. That is 181% of the 2025 profit.

Turnover

≈ €440,000 estimated

The micro format states no turnover.

Securities

€228,800

The 2025 accounts state mortgage mandates of €228,800, 1.4 times equity. The 2024 accounts did not.

Investments

€16,953 1.6 times depreciation
202320242025

Green is investment, beige is depreciation.

Filings

4 annual accounts 3 late
AprilJune31 JulyOctober2022202320242025

The 2022 accounts came in latest, 30 days after the end of the period.

Position in the sector

€163,428

Higher net result than 83% of companies in human health. The sector median is €59,541, over 21,360 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,332 companies had the same profile as LABNEST has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,332 companies, not a prediction for LABNEST. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 12-07-2022
  • founderdeed of 20-07-2022
  • 10 sharesdeed of 20-07-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0788689380
Registered-office move is in office as director · Gazette deed
Incorporation Founding capital of €1,000, 10 shares · Founded by · appointed as director · published on 20-07-2022 · Gazette deed
First establishment At the time the registered office was still in Menen.
All 11 events

Comparable companies

same main activity, similar in size and age
Company
LABNEST Kortrijk €366,969 €234,227 44.8% -
Dr. Tine Vanlancker Menen €393,360 €225,384 42.5% -
DR. OPHELIE VANDEMOORTELE Ledegem €344,426 €243,865 1.5% -
HCNC Bruges €373,020 €217,143 69.7% -
Cardiovision Destelbergen €366,224 €241,978 83.0% -
DR. EMILIE JANSSENS – HEMATOLOGIE Zulte €355,315 €245,520 82.7% -
CABINET MEDICAL DOCTEUR PIERRE-PHILIPPE GUILMOT Namur €391,399 €236,077 0.8% -

These companies have the same main activity as LABNEST: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €344,000 and €393,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 18-07-2022Normal situation
Activity
Specialist medical practiceNACE 86220and 1 other
Establishment unit
2.333.606.5018500 Kortrijk, registered on 18-07-2022
Financial year end
31 December
Peppol
Reachable since 04-12-2025
Company details

Annual accounts 2025

€366,969▼ 30.0%
Filing
Filed on 24-08-2026
Financials

Insights on LABNEST

LABNEST files the micro format. That format states no turnover. The gross margin rose from €72,367 in 2022 to €234,227 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about LABNEST

What is the company number of LABNEST?
The company number of LABNEST is 0788.689.380. The VAT number is the same number with BE in front: BE 0788.689.380.
Where is LABNEST based?
The registered office is at Sint-Margriete-Houtemlaan 12, 8500 Kortrijk.Company details
What does LABNEST do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of LABNEST?
LABNEST is a private limited company (BV).
When was LABNEST founded?
LABNEST was founded on 18-07-2022.
Is LABNEST still active?
Yes, LABNEST is an active enterprise in the KBO register.
What is the turnover of LABNEST?
The turnover in financial year 2025 is about €440,000. This figure is estimated from the gross margin of €234,227 and 40 comparable companies (NACE 86220). It probably lies between €370,000 and €580,000.Financials
Is LABNEST profitable?
In financial year 2025, LABNEST made a profit of €163,428.
Where can I find the annual accounts of LABNEST?
LABNEST filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of LABNEST due?
LABNEST must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.